Search for: "Teva Pharmaceuticals" Results 881 - 900 of 1,429
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Aug 2011, 5:18 am by Lawrence B. Ebert
The Mylan case is Teva Pharmaceuticals Industries Ltd. v. [read post]
25 Aug 2011, 4:15 pm by Phil
• Generic companies KRKA and Teva appear in the top five applicants for patents relating to Candesartan. [read post]
24 Aug 2011, 12:33 am by Marie Louise
Novartis (IPBiz) Simcor (Niacin, Simvastatin) – US: Abbott Laboratories files patent infringement complaint against Teva in response to Para IV challenge (Patent Docs) Vanos (Fluocinonide) – US: Medicis and Nycomed settle Vanos patent dispute (Patent Docs) Viagra (Sildenafil) – US: Pfizer’s patent on Viagra upheld by the EDVA: Pfizer v Teva (Rocket Docket IP Blog) (Patent Docs) (The IP Factor) [read post]
19 Aug 2011, 9:23 am by Stephen Jenei
   Teva Pharmaceuticals argued that the patent was invalid because anyone well-versed in the art of drug making would have known, from prior research, that sildenafil could be effective as an ED treatment. [read post]
16 Aug 2011, 11:35 pm by Marie Louise
PTO does not appear to invalidate very many gene patent method claims (Holman’s Biotech IP Blog) US: Machine-or-transformation test after Myriad: Implications to the prosecution of process claims (Patent Law Practice Center) US: Unsuccessful Qui Tam plaintiff asserting false marking claim not immune from costs award: Promote Innovation v Roche Diagnostics (Docket Report) US: FDA releases two medical device draft guidances (FDA Law Blog) US: BIO: Unleashing the promise of biotechnology (pt.4)… [read post]
15 Aug 2011, 9:55 am by Patrick G. Lee
Teva Pharmaceutical Industries Ltd., which has proposed a generic version of Viagra, argued that the patent was invalid because anyone well-versed in the art of drug making could have gleaned, from prior research, that sildenafil could be effective as an ED treatment. [read post]
15 Aug 2011, 7:32 am by Phil
(PFE) won a patent- infringement case that prevents Teva Pharmaceutical Industries Ltd. [read post]
12 Aug 2011, 10:06 am
The lawsuit arose from an Abbreviated New Drug Application filed with the Food and Drug Administration that had been filed by Teva Parenteral Medicines of Israel, alleging APP Pharmaceuticals LLC of Schaumburg, Illinois, and Barr Laboratories of Montvale, New Jersey. [read post]
9 Aug 2011, 8:24 pm by Eric Schweibenz
  In the Order, ALJ Rogers granted-in-part and denied-in-part non-parties Teva Pharmaceuticals USA, Inc. and Teva Parenteral Medicines, Inc. [read post]
3 Aug 2011, 3:31 am by Marie Louise
: Cour d’Appel Paris decision in Teva v Eli Lilly (Kluwer Patent Blog) US: CAFC confirms that isolated DNA may be patented: Association for Molecular Pathology v. [read post]
1 Aug 2011, 8:19 am
The seven defendants, Actavis Elizabeth LLC, Sun Pharmaceuticals, Sandoz Inc., Mylan Pharmaceuticals, Apotex Inc., Aurobindo Pharma Ltd., and Teva Pharmaceuticals, had filed an Abbreviated New Drug Application (ANDA) seeking to utilize Lilly's patented formula and claiming invalidity of Lilly's patent, No. 5,658,590, Treatment of attention-deficit/hyperactivity disorder, which has been issued by the US Patent Office. [read post]
27 Jul 2011, 4:06 pm by Lawrence B. Ebert
Caraco :Defendants-Appellees Caraco Pharmaceutical Labora- tories, Ltd. and Sun Pharmaceutical Industries, Ltd. [read post]
27 Jul 2011, 1:01 am by Marie Louise
KG (TTABlog) US: ALJ Rogers sets 17-month target date in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)   Products Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaints against APP Pharmaceuticals in Delaware and S D Indiana in response to Para IV certification filing (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of… [read post]
25 Jul 2011, 1:34 am by Lawrence B. Ebert
Mylan Inc. and Momenta Pharmaceuticals Inc. have each challenged Teva's patents on Copaxone.Separately, note the postGeneric drugs have slower approval route than new ones, backlogged by FDA staff shortage [read post]
20 Jul 2011, 4:04 am by Marie Louise
– Economic Times reports ‘Letter of Understanding’ between EU and India (Spicy IP) (Generic Pharmaceuticals and IP) France considers paralysing IP rights on the appearance of generic drugs (Class 46) India: Application of Orphan Drug Act to section 3(d)? [read post]
19 Jul 2011, 6:03 am by Mark Zamora
Here's the list for 2011 so far:  Potential Signals of Serious Risks/New Safety Information Identified by AERS, January to March 2011 Product Potential Signal of a Serious Risk/New Safety Information Additional Information (as of May 31, 2011) … [read post]